Presentation
13 March 2024 Nanobody-based fluorescent contrast agents for rapid and specific intra-operative tumor visualization
Sophie Hernot
Author Affiliations +
Abstract
Fluorescence molecular imaging has been shown to play a crucial role in enhancing decision-making in surgical oncology by providing real-time visualization of malignant tissue through the use of fluorescent targeted contrast agents. One prominent category of targeted molecules are Nanobodies®, antigen-binding fragments derived from camelid heavy chain-only antibodies. Nanobodies are renowned for their rapid and highly specific uptake by tumors, and combined with a fast blood clearance, they enable high-contrast imaging from one hour post-injection. Nanobodies targeting relevant biomarkers have shown to visualize small lesions in different tumor models including glioblastoma, colon cancer, pancreatic cancer, liver metastasis and intraperitoneal metastasis. However, research also highlighted the critical role of the choice of fluorophore and conjugation chemistry on the Nanobodies’ pharmacokinetics. To bridge the gap between mouse and human, we are exploring the potential of Nanobodies in larger animals and are assessing the feasibility to apply fluorescent Nanobodies to assess tumor-margins status of surgical resection specimens in an ex vivo incubation study.
Conference Presentation
© (2024) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Sophie Hernot "Nanobody-based fluorescent contrast agents for rapid and specific intra-operative tumor visualization", Proc. SPIE PC12825, Molecular-Guided Surgery: Molecules, Devices, and Applications X, PC128250N (13 March 2024); https://doi.org/10.1117/12.3012726
Advertisement
Advertisement
KEYWORDS
Tumors

Contrast agents

Visualization

Animal model studies

Animals

Colorectal cancer

Dyes

RELATED CONTENT


Back to Top